Myanmar Health Sciences Research Journal
Volume 28, Number 2
TITLE: Effect of Clopidogrel on C-reactive Protein and Malondialdehyde Level in Hypercholesterolemic Subjects
AUTHOR: Myat Htet Thin, Soe Soe Htwe, Khin Mar Myint & May Hla Thwin
SOURCE: Myanmar Health Sciences Research Journal
ABSTRACT: Cardiovascular diseases are the number one cause of death globally in which thrombotic complications play a major role. Recent investigations have indicated that inflammation and free radicals are involved throughout the atherogenic process. The use of antiplatelet, clopidogrel, has been one of the major pharmacological interventions in the treatment of myocardial infarction, stroke and peripheral vascular disease. The aim of this study was to identify whether clopidogrel attenuated inflammatory activity determined by C-reactive protein (CRP) and oxidative stress determined by malondialdehyde (MDA). Bleeding time was evaluated for the safety profile of the drug. The study was pre (baseline) -and post (4 weeks after clopidogrel therapy) -design which included twenty-seven, 40 to 60 years old, hypercholesterolemic subjects who had taken 75 mg clopidogrel daily. The serum CRP and plasma MDA levels were measured by turbidimetric method and thiobarbituric acid reaction test, respectively. Bleeding time was determined according to Duke method. There were 8.09% reduction in serum CRP and 18.79% reduction in plasma MDA at 4th week after clopidogrel therapy. Bleeding time at 4th week after clopidogrel therapy was significantly prolonged (11.46%) compared to baseline although they were within the normal range. During the study period, clopidogrel was well tolerated by all subjects. It was concluded that clopidogrel effectively reduced the levels of CRP and MDA and it prolongs bleeding time. This study suggested that clopidogrel could have the beneficial effects in the prevention and treatment of atherosclerosis by its anti-inflammatory and anti-oxidant actions beyond its antiplatelet activity with a favourable safety profile.
SUBJECT HEADINGS: Clopidogrel, C-reactive protein, Malondialdehyde, Bleeding time